References
- Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2(7635), 1380–1382 (1969).
- Dowdall M. Highlighting the future potential of PCSK9-targeted therapeutics. Clin. Lipidol. 7(6), 599–601 (2012).
- Strong JP, Malcom GT, Oalmann MC et al. The PDAY Study: natural history, risk factors, and pathophysiology: Pathological Determinants of Atherosclerosis in Youth. Ann. NY Acad. Sci. 811, 226–235 (1997).
- US Preventive Services Taskforce. Screening for lipid disorders in adults. Am. Fam. Physician 80(11), 1273–1274 (2009).
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl. 5), S213–S256 (2011).
- Williams RR. Understanding genetic and environmental risk factors in susceptible persons. West. J. Med. 4, 799–806 (1984).
- Ritchie S, Murphy EC, Ice C et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics 126, 260–265 (2010).
- Fogg TT, Chin-To F, John C et al. Knowledge, perception, and behaviors of relatives of people with premature heart disease: a systematic literature review. Circulation 124, 958–964 (2011).
- Foody JM. Familial hypercholesterolemia: an underrecognized but significant concern in cardiology practice. Clin. Cardiol. 37(2), 119–125 (2014).
- Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J. Clin. Lipidol. 4, 338–341 (2010).
- Ned RM, Sijbrands JG. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr. 3, RRN1238 (2011).
- Oliva J, Lopez-Bastida J, Moreno SG et al. Cost–effectiveness analysis of a genetic screening program in the close relatives of spanish patients with familial hypercholesterolemia. Rev. Esp. Cardiol. 62, 57–65 (2009).
- Hallowell N, Jenkins N, Douglas M et al. Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J. Community Genet. 2(4), 249–257 (2011).
- de Wert G. Cascade screening: whose information is it anyway? Eur. J. Hum. Genet. 13, 397–398 (2005).
- Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ et al. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet 357, 165–168 (2001).
- Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337, a1095 (2008).
- Pocovi M, Civiera F, Alonso R et al. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semen. Vasc. Med. 4, 67–74 (2004).
- O’Brien EC, Roe MT, Fraulo ES et al. Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial hypercholesterolemia registry. Am. Heart J. 167 (3), 342–349 (2014).